Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Guiding the humoral response against HIV-1 toward a MPER adjacent region by immunization with a VLP-formulated antibody-selected envelope variant.

Beltran-Pavez C, Ferreira CB, Merino-Mansilla A, Fabra-Garcia A, Casadella M, Noguera-Julian M, Paredes R, Olvera A, Haro I, Brander C, Garcia F, Gatell JM, Yuste E, Sanchez-Merino V.

PLoS One. 2018 Dec 19;13(12):e0208345. doi: 10.1371/journal.pone.0208345. eCollection 2018.

2.

Characterization of broadly neutralizing antibody responses to HIV-1 in a cohort of long term non-progressors.

González N, McKee K, Lynch RM, Georgiev IS, Jimenez L, Grau E, Yuste E, Kwong PD, Mascola JR, Alcamí J.

PLoS One. 2018 Mar 20;13(3):e0193773. doi: 10.1371/journal.pone.0193773. eCollection 2018.

3.

Structural Study of a New HIV-1 Entry Inhibitor and Interaction with the HIV-1 Fusion Peptide in Dodecylphosphocholine Micelles.

Pérez Y, Gómara MJ, Yuste E, Gómez-Gutierrez P, Pérez JJ, Haro I.

Chemistry. 2017 Aug 25;23(48):11703-11713. doi: 10.1002/chem.201702531. Epub 2017 Aug 3.

PMID:
28677862
4.

Lipid raft-like liposomes used for targeted delivery of a chimeric entry-inhibitor peptide with anti-HIV-1 activity.

Gómara MJ, Pérez-Pomeda I, Gatell JM, Sánchez-Merino V, Yuste E, Haro I.

Nanomedicine. 2017 Feb;13(2):601-609. doi: 10.1016/j.nano.2016.08.023. Epub 2016 Aug 24.

PMID:
27565689
5.

Detection of Broadly Neutralizing Activity within the First Months of HIV-1 Infection.

Sanchez-Merino V, Fabra-Garcia A, Gonzalez N, Nicolas D, Merino-Mansilla A, Manzardo C, Ambrosioni J, Schultz A, Meyerhans A, Mascola JR, Gatell JM, Alcami J, Miro JM, Yuste E.

J Virol. 2016 May 12;90(11):5231-5245. doi: 10.1128/JVI.00049-16. Print 2016 Jun 1.

6.

Antibody-Based Preventive and Therapeutic Strategies Against HIV.

Fabra-Garcia A, Beltran C, Sanchez-Merino V, Yuste E.

Curr HIV Res. 2016;14(3):260-9. Review.

PMID:
26957200
7.

Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor.

Gómara MJ, Sánchez-Merino V, Paús A, Merino-Mansilla A, Gatell JM, Yuste E, Haro I.

Biochim Biophys Acta. 2016 Jun;1860(6):1139-48. doi: 10.1016/j.bbagen.2016.02.008. Epub 2016 Feb 22.

PMID:
26905802
8.

HIV-1 Dual Infected LTNP-EC Patients Developed an Unexpected Antibody Cross-Neutralizing Activity.

Pernas M, Sanchez-Merino V, Casado C, Merino-Mansilla A, Olivares I, Yuste E, Lopez-Galindez C.

PLoS One. 2015 Aug 10;10(8):e0134054. doi: 10.1371/journal.pone.0134054. eCollection 2015.

9.

Systematic analysis of intracellular trafficking motifs located within the cytoplasmic domain of simian immunodeficiency virus glycoprotein gp41.

Postler TS, Bixby JG, Desrosiers RC, Yuste E.

PLoS One. 2014 Dec 5;9(12):e114753. doi: 10.1371/journal.pone.0114753. eCollection 2014.

10.

Glycosystems in nanotechnology: Gold glyconanoparticles as carrier for anti-HIV prodrugs.

Chiodo F, Marradi M, Calvo J, Yuste E, Penadés S.

Beilstein J Org Chem. 2014 Jun 12;10:1339-46. doi: 10.3762/bjoc.10.136. eCollection 2014.

11.

HIV-1 inhibiting capacity of novel forms of presentation of GB virus C peptide domains is enhanced by coordination to gold compounds.

Gómara MJ, Galatola R, Gutiérrez A, Gimeno MC, Gatell JM, Sánchez-Merino V, Yuste E, Haro I.

Curr Med Chem. 2014;21(2):238-50. Review.

PMID:
24083612
12.

Evolution of broadly cross-reactive HIV-1-neutralizing activity: therapy-associated decline, positive association with detectable viremia, and partial restoration of B-cell subpopulations.

Ferreira CB, Merino-Mansilla A, Llano A, Pérez I, Crespo I, Llinas L, Garcia F, Gatell JM, Yuste E, Sanchez-Merino V.

J Virol. 2013 Nov;87(22):12227-36. doi: 10.1128/JVI.02155-13. Epub 2013 Sep 4.

13.

Expansion of antibody secreting cells and modulation of neutralizing antibody activity in HIV infected individuals undergoing structured treatment interruptions.

Llano A, Carrillo J, Mothe B, Ruiz L, Marfil S, García E, Yuste E, Sánchez V, Clotet B, Blanco J, Brander C.

J Transl Med. 2013 Feb 22;11:48. doi: 10.1186/1479-5876-11-48.

14.

Low-replicating viruses and strong anti-viral immune response associated with prolonged disease control in a superinfected HIV-1 LTNP elite controller.

Pernas M, Casado C, Arcones C, Llano A, Sánchez-Merino V, Mothe B, Vicario JL, Grau E, Ruiz L, Sánchez J, Telenti A, Yuste E, Brander C, Galíndez CL.

PLoS One. 2012;7(2):e31928. doi: 10.1371/journal.pone.0031928. Epub 2012 Feb 24.

15.

Evidence against extracellular exposure of a highly immunogenic region in the C-terminal domain of the simian immunodeficiency virus gp41 transmembrane protein.

Postler TS, Martinez-Navio JM, Yuste E, Desrosiers RC.

J Virol. 2012 Jan;86(2):1145-57. doi: 10.1128/JVI.06463-11. Epub 2011 Nov 9.

16.

A cell-to-cell HIV transfer assay identifies humoral responses with broad neutralization activity.

Sánchez-Palomino S, Massanella M, Carrillo J, García A, García F, González N, Merino A, Alcamí J, Bofill M, Yuste E, Gatell JM, Clotet B, Blanco J.

Vaccine. 2011 Jul 18;29(32):5250-9. doi: 10.1016/j.vaccine.2011.05.016. Epub 2011 May 24.

PMID:
21609746
17.

Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia.

Medina-Ramírez M, Sánchez-Merino V, Sánchez-Palomino S, Merino-Mansilla A, Ferreira CB, Pérez I, González N, Alvarez A, Alcocer-González JM, García F, Gatell JM, Alcamí J, Yuste E.

J Virol. 2011 Jun;85(12):5804-13. doi: 10.1128/JVI.02482-10. Epub 2011 Apr 6.

18.

Gold nanoparticles coated with oligomannosides of HIV-1 glycoprotein gp120 mimic the carbohydrate epitope of antibody 2G12.

Marradi M, Di Gianvincenzo P, Enríquez-Navas PM, Martínez-Ávila OM, Chiodo F, Yuste E, Angulo J, Penadés S.

J Mol Biol. 2011 Jul 29;410(5):798-810. doi: 10.1016/j.jmb.2011.03.042. Epub 2011 Mar 25.

PMID:
21440555
19.

Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys.

Johnson PR, Schnepp BC, Zhang J, Connell MJ, Greene SM, Yuste E, Desrosiers RC, Clark KR.

Nat Med. 2009 Aug;15(8):901-6. doi: 10.1038/nm.1967. Epub 2009 May 17.

20.

Immunization with single-cycle SIV significantly reduces viral loads after an intravenous challenge with SIV(mac)239.

Jia B, Ng SK, DeGottardi MQ, Piatak M, Yuste E, Carville A, Mansfield KG, Li W, Richardson BA, Lifson JD, Evans DT.

PLoS Pathog. 2009 Jan;5(1):e1000272. doi: 10.1371/journal.ppat.1000272. Epub 2009 Jan 23.

21.

Glycosylation of gp41 of simian immunodeficiency virus shields epitopes that can be targets for neutralizing antibodies.

Yuste E, Bixby J, Lifson J, Sato S, Johnson W, Desrosiers R.

J Virol. 2008 Dec;82(24):12472-86. doi: 10.1128/JVI.01382-08. Epub 2008 Oct 1.

22.

Potent antibody-mediated neutralization and evolution of antigenic escape variants of simian immunodeficiency virus strain SIVmac239 in vivo.

Sato S, Yuste E, Lauer WA, Chang EH, Morgan JS, Bixby JG, Lifson JD, Desrosiers RC, Johnson WE.

J Virol. 2008 Oct;82(19):9739-52. doi: 10.1128/JVI.00871-08. Epub 2008 Jul 30.

23.

Use of the median for the evaluation of blood pressure self-measurement (BPSM).

Lijarcio MA, Yuste EA, Senso AA, Aparicio JB, Ruiz JA, García MD, Tobal FG, Llarena ML, Garcia CM, Cano FP, Castán JF, Perez-Monteoliva NR, Santos NS.

Eur J Intern Med. 2007 Jan;18(1):31-4.

PMID:
17223039
24.

Balancing selection and the evolution of functional polymorphism in Old World monkey TRIM5alpha.

Newman RM, Hall L, Connole M, Chen GL, Sato S, Yuste E, Diehl W, Hunter E, Kaur A, Miller GM, Johnson WE.

Proc Natl Acad Sci U S A. 2006 Dec 12;103(50):19134-9. Epub 2006 Dec 1.

25.

A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120.

Beddows S, Franti M, Dey AK, Kirschner M, Iyer SP, Fisch DC, Ketas T, Yuste E, Desrosiers RC, Klasse PJ, Maddon PJ, Olson WC, Moore JP.

Virology. 2007 Apr 10;360(2):329-40. Epub 2006 Nov 28.

26.

Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma.

Yuste E, Sanford HB, Carmody J, Bixby J, Little S, Zwick MB, Greenough T, Burton DR, Richman DD, Desrosiers RC, Johnson WE.

J Virol. 2006 Mar;80(6):3030-41.

27.

Incidence of acute respiratory distress syndrome and its relation to age.

Manzano F, Yuste E, Colmenero M, Aranda A, García-Horcajadas A, Rivera R, Fernández-Mondéjar E; Granada Respiratory Failure Study Group.

J Crit Care. 2005 Sep;20(3):274-80.

PMID:
16253798
28.

Confronting and eradicating an epidemic of bacteraemia.

Mayor S, Ramírez N, Rodríguez A, Mañé N, Miret X, Yuste E.

EDTNA ERCA J. 2005 Apr-Jun;31(2):104-6.

PMID:
16180557
29.

Virion envelope content, infectivity, and neutralization sensitivity of simian immunodeficiency virus.

Yuste E, Johnson W, Pavlakis GN, Desrosiers RC.

J Virol. 2005 Oct;79(19):12455-63.

30.

Few mutations in the 5' leader region mediate fitness recovery of debilitated human immunodeficiency type 1 viruses.

Yuste E, Bordería AV, Domingo E, López-Galíndez C.

J Virol. 2005 May;79(9):5421-7.

31.
32.

[An outbreak of gram-negative bacteremia (GNB), especially enterobacter cloacae, in patients with long-term tunnelled haemodialysis catheters].

Rodríguez Jornet A, García García M, Mariscal D, Fontanals D, Cortés P, Coll P, Falcó J, Ramírez N, Mayor S, Mañé N, Miret X, Yuste E.

Nefrologia. 2003 Jul-Aug;23(4):333-43. Spanish.

33.

Frequency-dependent selection in human immunodeficiency virus type 1.

Yuste E, Moya A, López-Galíndez C.

J Gen Virol. 2002 Jan;83(Pt 1):103-6.

PMID:
11752706
34.

In vitro analysis of human immunodeficiency virus type 1 resistance to nevirapine and fitness determination of resistant variants.

Iglesias-Ussel MD, Casado C, Yuste E, Olivares I, López-Galíndez C.

J Gen Virol. 2002 Jan;83(Pt 1):93-101.

PMID:
11752705
35.

Virus population dynamics, fitness variations and the control of viral disease: an update.

Domingo E, Mas A, Yuste E, Pariente N, Sierra S, Gutiérrez-Riva M, Menéndez-Arias L.

Prog Drug Res. 2001;57:77-115. Review.

PMID:
11728003
36.

[Patients with end-stage chronic renal insufficiency on programmed withdrawal from dialysis].

Rodríguez Jornet A, García García M, Hernando P, Ramírez Vaca J, Padilla J, Ponz E, Almirall J, Rué M, Martínez Ocaña JC, Yuste E, Cañellas M, Ciurana JM, Royo C, García Moreno S.

Nefrologia. 2001 Mar-Apr;21(2):150-9. Spanish.

37.
38.

Drastic fitness loss in human immunodeficiency virus type 1 upon serial bottleneck events.

Yuste E, Sánchez-Palomino S, Casado C, Domingo E, López-Galíndez C.

J Virol. 1999 Apr;73(4):2745-51.

39.

Random important alterations in HIV-1 viral quasispecies after antiviral treatment.

Sánchez-Palomino S, Olivares I, Yuste E, Richman DD, López-Galíndez C.

Antivir Ther. 1996 Dec;1(4):225-36.

PMID:
11324825
40.

Nursing protocol for manipulation of haemodialysis catheters.

Pons R, Blasco C, Jiménez J, López J, Mañé N, Marquina D, Moya C, Ortigosa L, Padilla J, Pérez O, Ramírez N, Ramírez J, Solano M, Yuste E, Soley I, Rodríguez A, Ponz E.

EDTNA ERCA J. 1996 Oct-Dec;22(4):39-42.

PMID:
10723350
41.

Estimation of the prevalence of diabetes mellitus diagnosed, and incidence of type 1 (insulin-dependent) diabetes mellitus in the Avila Health Care region of Spain.

Calle-Pascual AL, Vicente A, Martin-Alvarez PJ, Yuste E, de Matias J, Calle JR, Sanchez R.

Diabetes Res Clin Pract. 1993 Jan;19(1):75-81.

PMID:
8472622
42.

Behaviour modification in obese subjects with type 2 diabetes mellitus.

Calle-Pascual AL, Rodriguez C, Camacho F, Sanchez R, Martin-Alvarez PJ, Yuste E, Hidalgo I, Diaz RJ, Calle JR, Charro AL.

Diabetes Res Clin Pract. 1992 Feb;15(2):157-62.

PMID:
1563332
43.

Effect of the infusion of p-Glu-His-Ala-OH, analog of the anorexigenic peptide, on the insulin response induced by intravenous glucose. Preliminary results with obese subjects.

Calle-Pascual AL, Rodriguez C, Yuste E, de Matias J, Schally AV, Martin-Vaquero P, Castillo P, Charro AL.

Horm Metab Res Suppl. 1992;26:27-31.

PMID:
1490689
44.

Effect of weight loss on insulin sensitivity and cardiovascular risk factors in glucose tolerant and intolerant obese subjects.

Calle-Pascual AL, Rodriguez C, Martin-Alvarez PJ, Camacho F, Calle JR, Yuste E, Hildago I, Diaz RJ, Martin-Vaquero P, Santiago M, et al.

Diabete Metab. 1991 Jul-Aug;17(4):404-9.

PMID:
1915998
45.

Association of a thyrotropin-secreting pituitary adenoma and a thyroid follicular carcinoma.

Calle-Pascual AL, Yuste E, Martin P, Aramendi T, Garcia-Mauriño ML, Argente J, Catalan MJ, Uria J, Cabranes JA, Charro AL.

J Endocrinol Invest. 1991 Jun;14(6):499-502.

PMID:
1774446
46.

[Urine glucose in self-monitoring of the diabetic patient].

de Matías JM, Yuste E, Sánchez R, Vaquero PM.

Med Clin (Barc). 1990 Mar 31;94(12):478. Spanish. No abstract available.

PMID:
2366611
47.

Programme of education for obese patients. Preliminary results after one year.

Calle-Pascual AL, Rodriguez C, Hernandez MJ, Martin PJ, Yuste E, Garcia MA, Matias J, Martin-Vaquero P, Sanchez R.

Diabete Metab. 1989 Nov-Dec;15(6):403-8.

PMID:
2628042
48.

[Programs of diabetological education: a basic tool in the treatment of diabetes mellitus].

Calle-Pascual AL, Sánchez R, García MA, Hernández MJ, Yuste E, Benito J, Matías J, Rodríguez C, Bordiu E.

Med Clin (Barc). 1989 Apr 22;92(15):567-70. Spanish.

PMID:
2666769

Supplemental Content

Support Center